Skip to main content
. 2021 May 31;13(6):817. doi: 10.3390/pharmaceutics13060817

Figure 1.

Figure 1

In vivo evaluation of effect of GalNAc conjugation on ASOs’ activity. (a) The expression levels of miRNA-122-targeted mRNAs in the livers of mice (6-week-old male C57Bl6/J, n = 3–6) after 7 days of injection at a dosage of 5 mg/kg or 10 mg/kg of tinyLNA. (b) Their corresponding serum cholesterol levels and kidney and liver transaminase levels. (c) The expression levels of miRNA-122-targeted mRNAs in the livers of mice (6-week-old male C57Bl6/J, n = 3–4) after 7 days of injection at a dosage of 5 mg/kg for tinyLNA and tL-5G3 or 17.5 nmol/kg for CtrASO. (d–f) Their corresponding serum cholesterol levels, miRNA-122 expression levels, and kidney and liver transaminase levels, respectively. ** p < 0.01 and * p < 0.05 (vs. saline).